-
Je něco špatně v tomto záznamu ?
ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure
A. Østergaard, M. Fiocco, H. de Groot-Kruseman, AV. Moorman, A. Vora, M. Zimmermann, M. Schrappe, A. Biondi, G. Escherich, J. Stary, C. Imai, T. Imamura, M. Heyman, K. Schmiegelow, R. Pieters
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, metaanalýza
NLK
ProQuest Central
od 2000-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Nursing & Allied Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
- MeSH
- akutní lymfatická leukemie * genetika farmakoterapie mortalita terapie MeSH
- fúzní onkogenní proteiny * genetika MeSH
- lidé MeSH
- míra přežití MeSH
- protein ETS, translokační varianta 6 * MeSH
- protein PEBP2A2 * genetika MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- protoonkogenní proteiny c-ets * genetika MeSH
- represorové proteiny * genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
Recent trials show 5-year survival rates >95% for ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL). Since treatment has many side effects, an overview of cumulative drug doses and intensities between eight international trials is presented to characterize therapy needed for cure. A meta-analysis was performed as a comprehensive summary of survival outcomes at 5 and 10 years. For drug dose comparison in non-high risk trial arms, risk group distribution was applied to split the trials into two groups: trial group A with ~70% (range: 63.5-75%) of patients in low risk (LR) (CCLSG ALL2004, CoALL 07-03, NOPHO ALL2008, UKALL2003) and trial group B with ~45% (range: 38.7-52.7%) in LR (AIEOP-BFM ALL 2000, ALL-IC BFM ALL 2002, DCOG ALL10, JACLS ALL-02). Meta-analysis did not show evidence of heterogeneity between studies in trial group A LR and medium risk (MR) despite differences in treatment intensity. Statistical heterogeneity was present in trial group B LR and MR. Trials using higher cumulative dose and intensity of asparaginase and pulses of glucocorticoids and vincristine showed better 5-year event-free survival but similar overall survival. Based on similar outcomes between trials despite differences in therapy intensity, future trials should investigate, to what extent de-escalation is feasible for ETV6::RUNX1 ALL.
Associazione Italiana di Ematologia e Oncologia Pediatrica Bologna Italy
Berlin Frankfurt Münster Study Group Frankfurt Germany
Childhood Acute Lymphoblastic Leukemia study group Hamburg Germany
Children's Cancer and Leukemia Study Group Nagoya Japan
Department of Haematology Great Ormond Street Hospital London UK
Department of Paediatric Haematology and Oncology Hannover Medical School 30625 Hannover Germany
Department of Paediatric Oncology Karolinska University Hospital Stockholm Sweden
Department of Paediatrics University Medical Centre Schleswig Holstein Kiel Germany
Department of Pediatrics University of Milano Bicocca Monza Italy
Dutch Childhood Oncology Group Utrecht The Netherlands
Japan Childhood Leukemia Study Group Nagoya Japan
Mathematical Institute Leiden University Leiden The Netherlands
Nordic Society of Paediatric Haematology and Oncology Nordic and Baltic Countries Uppsala Sweden
Nordic Society of Paediatric Haematology and Oncology Nordic Countries Uppsala Sweden
Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands
United Kingdom Acute Lymphoblastic Leukaemia study group Liverpool UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019883
- 003
- CZ-PrNML
- 005
- 20241024111016.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-024-02287-7 $2 doi
- 035 __
- $a (PubMed)38844578
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Østergaard, Anna $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
- 245 10
- $a ETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure / $c A. Østergaard, M. Fiocco, H. de Groot-Kruseman, AV. Moorman, A. Vora, M. Zimmermann, M. Schrappe, A. Biondi, G. Escherich, J. Stary, C. Imai, T. Imamura, M. Heyman, K. Schmiegelow, R. Pieters
- 520 9_
- $a Recent trials show 5-year survival rates >95% for ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL). Since treatment has many side effects, an overview of cumulative drug doses and intensities between eight international trials is presented to characterize therapy needed for cure. A meta-analysis was performed as a comprehensive summary of survival outcomes at 5 and 10 years. For drug dose comparison in non-high risk trial arms, risk group distribution was applied to split the trials into two groups: trial group A with ~70% (range: 63.5-75%) of patients in low risk (LR) (CCLSG ALL2004, CoALL 07-03, NOPHO ALL2008, UKALL2003) and trial group B with ~45% (range: 38.7-52.7%) in LR (AIEOP-BFM ALL 2000, ALL-IC BFM ALL 2002, DCOG ALL10, JACLS ALL-02). Meta-analysis did not show evidence of heterogeneity between studies in trial group A LR and medium risk (MR) despite differences in treatment intensity. Statistical heterogeneity was present in trial group B LR and MR. Trials using higher cumulative dose and intensity of asparaginase and pulses of glucocorticoids and vincristine showed better 5-year event-free survival but similar overall survival. Based on similar outcomes between trials despite differences in therapy intensity, future trials should investigate, to what extent de-escalation is feasible for ETV6::RUNX1 ALL.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a akutní lymfatická leukemie $x genetika $x farmakoterapie $x mortalita $x terapie $7 D054198
- 650 12
- $a protein PEBP2A2 $x genetika $7 D050676
- 650 12
- $a protein ETS, translokační varianta 6 $7 D000097764
- 650 12
- $a fúzní onkogenní proteiny $x genetika $7 D015514
- 650 12
- $a protoonkogenní proteiny c-ets $x genetika $7 D050783
- 650 12
- $a represorové proteiny $x genetika $7 D012097
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 700 1_
- $a Fiocco, Marta $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Mathematical Institute, Leiden University, Leiden, The Netherlands $u Department of Biomedical Science, Section Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a de Groot-Kruseman, Hester $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands $u Dutch Childhood Oncology Group (DCOG), Utrecht, The Netherlands
- 700 1_
- $a Moorman, Anthony V $u Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $u United Kingdom Acute Lymphoblastic Leukaemia (UKALL) study group, Liverpool, UK $1 https://orcid.org/0000000297816107
- 700 1_
- $a Vora, Ajay $u United Kingdom Acute Lymphoblastic Leukaemia (UKALL) study group, Liverpool, UK $u Department of Haematology, Great Ormond Street Hospital, London, UK $1 https://orcid.org/0000000221674368
- 700 1_
- $a Zimmermann, Martin $u Department of Paediatric Haematology and Oncology, Hannover Medical School, 30625, Hannover, Germany $u Berlin-Frankfurt-Münster Study Group (BFM), Frankfurt, Germany
- 700 1_
- $a Schrappe, Martin $u Berlin-Frankfurt-Münster Study Group (BFM), Frankfurt, Germany $u Department of Paediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Biondi, Andrea $u Department of Pediatrics, University of Milano-Bicocca, Monza, Italy $u Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP), Bologna, Italy $1 https://orcid.org/0000000267576173
- 700 1_
- $a Escherich, Gabriele $u Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany $u Childhood Acute Lymphoblastic Leukemia study group (CoALL), Hamburg, Germany
- 700 1_
- $a Stary, Jan $u Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Imai, Chihaya $u Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan $u Children's Cancer and Leukemia Study Group (CCLSG), Nagoya, Japan $1 https://orcid.org/0000000174353464
- 700 1_
- $a Imamura, Toshihiko $u Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan $u Japan Childhood Leukemia Study Group (JACLS), Nagoya, Japan $1 https://orcid.org/0000000257274470
- 700 1_
- $a Heyman, Mats $u Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden $u Department of Paediatric Oncology, Karolinska University Hospital, Stockholm, Sweden $u Nordic Society of Paediatric Haematology and Oncology (NOPHO), Nordic Countries, Uppsala, Sweden $1 https://orcid.org/0000000176371949
- 700 1_
- $a Schmiegelow, Kjeld $u Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark $u Nordic Society of Paediatric Haematology and Oncology (NOPHO), Nordic and Baltic Countries, Uppsala, Sweden $1 https://orcid.org/0000000208294993
- 700 1_
- $a Pieters, Rob $u Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. r.pieters@prinsesmaximacentrum.nl $u Dutch Childhood Oncology Group (DCOG), Utrecht, The Netherlands. r.pieters@prinsesmaximacentrum.nl $1 https://orcid.org/0000000329973570
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 38, č. 7 (2024), s. 1477-1487
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38844578 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111010 $b ABA008
- 999 __
- $a ok $b bmc $g 2202225 $s 1231856
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 38 $c 7 $d 1477-1487 $e 20240606 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20241015
